Related by context. All words. (Click for frequent words.) 68 Serious Adverse Events 67 DLTs 66 TEAEs 66 Adverse events 66 AEs 65 events SAEs 65 treatment emergent adverse 65 events AEs 64 concomitant medications 64 posaconazole 64 ALT flares 63 QTc prolongation 63 dose limiting toxicities 63 laboratory abnormalities 63 treatment emergent AEs 62 definite stent thrombosis 62 thromboembolic events 61 events TEAEs 61 hematologic toxicity 61 discontinuations 61 hypoglycemic events 61 severe hypersensitivity reactions 61 Postoperative complications 60 hematologic adverse 60 adverse reactions ≥ 60 ADEs 60 ocular adverse 60 neuropsychiatric events 60 placebo controlled studies 60 hypersensitivity reactions 60 transaminase elevations 60 COPD exacerbations 59 hepatotoxicity 59 Teriflunomide 59 intravenous bisphosphonates 59 GSK# [001] 59 ALT elevations 59 febrile neutropenia 59 nonfatal MI 59 mg kg dose 59 Hypersensitivity reactions 59 Serious AEs 59 infusion reactions 59 Adverse reactions 59 hypersensitivity reaction 59 hematological adverse 58 placebo controlled clinical trials 58 severe exacerbations 58 myelosuppression 58 elevated ALT 58 Serious adverse reactions 58 Serious Adverse Event 58 Toxicities 58 TNF antagonist 58 hypersensitivity allergic reactions 58 hepatic adverse 58 REYATAZ r arm 58 intracranial hemorrhage ICH 58 adverse reactions 58 ECG abnormalities 58 myocardial infarctions 58 FluCAM arm 58 endophthalmitis 58 evaluable subjects 58 evaluable 58 Infusion Reactions Severe 58 discontinuations due 57 virologic failure 57 FOLPI 57 thromboembolic 57 prespecified 57 mycophenolate mofetil 57 Torsades de Pointes 57 TDF FTC 57 PREZISTA r arm 57 renal toxicity 57 Treatment emergent adverse 57 ipsilateral stroke 57 neutropenia dehydration dyspnea 57 recurrent DVT 57 ug dose 57 cerebrovascular events 57 COPD exacerbation 57 Thrombotic events 57 Exacerbations 57 HCV SPRINT 57 Febrile neutropenia 57 pheochromocytoma 57 RCTs 57 Hepatotoxicity 57 dosing cohorts 57 Renal impairment 57 nonvertebral fractures 57 hematological toxicities 57 elotuzumab 57 rizatriptan 57 EXJADE 56 arterial thromboembolic events 56 splenectomized patients 56 TYSABRI treated 56 randomized controlled trials RCTs 56 APTIVUS r 56 leucopenia 56 hypomagnesemia 56 recurrent VTE 56 sustained ventricular tachycardia 56 MACCE 56 ARCOXIA 56 prolonged QT interval 56 ARCALYST ® 56 reinfarction 56 incidence ≥ 56 virological failure 56 hypercalcemia 56 certolizumab 56 adverse reactions occurring 56 myopathy rhabdomyolysis 56 external genital lesions 56 vaccinees 56 β blockers 56 hemorrhagic complications 56 severe neutropenia 56 oxycodone CR 56 RSD# oral 56 teriflunomide 56 Primary endpoints 56 haematologic 56 ruboxistaurin 56 bivariate analyzes 56 revascularizations 56 liver transaminases 56 QT prolongation 56 NATRECOR ® 56 CANCIDAS 56 recurrent venous thromboembolism 56 bacteremia 56 Stent thrombosis 56 flutamide 56 hepatic failure 56 Hypotension 56 anaphylactoid reactions 56 gastrointestinal toxicities 56 Adverse Events 55 ertapenem 55 secondary efficacy endpoints 55 montelukast 55 necrotizing pancreatitis 55 hypoglycemic episodes 55 ABC/3TC 55 CIMZIA ™ 55 invasive aspergillosis 55 thrombotic events 55 biologic DMARD 55 neurologic symptoms 55 pericardial effusion 55 UPLYSO 55 NOLVADEX 55 ACCORD Lipid 55 virologic breakthrough 55 PRADAXA 55 syncopal 55 patients evaluable 55 interstitial pneumonia 55 R# #mg BID 55 pyrexia mucositis sepsis febrile 55 hypophosphatemia 55 rFVIIa 55 vasogenic edema 55 angioedema 55 diarrhea nausea fatigue 55 exacerbations 55 HBeAg positive 55 salmeterol HFA MDI 55 VT VF 55 mcg BID 55 anemia neutropenia 55 Myelosuppression 55 microbiologically evaluable 55 HBeAg negative patients 55 intracerebral hemorrhage 55 VFEND 55 tacrolimus ointment 55 KRAS mutations occur 55 composite endpoint 55 mcg albinterferon alfa 2b 55 ATACAND 55 beta blocker therapy 55 hemorrhagic cystitis 55 ximelagatran 55 lumiracoxib 55 adverse reactions observed 55 periprocedural 55 Anaphylactic reactions 55 candidemia 55 QTc 55 nadroparin 55 neutropenia 54 thromboembolic complications 54 VIIBRYD 54 ZYVOX 54 multicenter trials 54 febuxostat 54 statistical significance p 54 DAS# CRP 54 antiepileptics 54 voriconazole 54 PREZISTA r 54 NNRTI resistance 54 neuropsychiatric symptoms 54 dose cohorts 54 HBeAg positive patients 54 adalimumab 54 FOLFIRI 54 gadobutrol 54 mcg QD 54 advanced adenomas 54 serum HCV RNA 54 thorough QT 54 genotypic resistance 54 clinically meaningful differences 54 Telithromycin 54 hypocalcemia 54 antimuscarinic 54 tapentadol ER 54 eosinophilic pneumonia 54 mucocutaneous reactions 54 OAB symptoms 54 incontinence episodes 54 lopinavir r arm 54 receiving INTRON 54 INVANZ 54 ARIXTRA 54 nonfatal stroke 54 asthma exacerbations 54 thrombocytopenia 54 prospectively defined 54 dosage regimens 54 secondary efficacy endpoint 54 RAPTIVA 54 dysglycemia 54 NYHA Class II 54 susceptible isolates 54 generalized edema 54 hepatitis C genotype 54 XIENCE V PROMUS Stent 54 FDA Adverse Event 54 mg administered orally 54 pentoxifylline 54 oral diclofenac 54 stent thromboses 54 atypical femur fractures 54 lenalidomide dexamethasone 54 double blinded placebo 54 histologically proven 54 peripheral sensory neuropathy 54 Dermatologic Toxicity Dermatologic toxicities 54 Complication rates 54 ribavirin therapy 54 thrombotic complications 54 Peripheral edema 54 Adverse Event 54 ventricular fibrillation VF 54 CRp 54 vismodegib 54 postmarketing 54 hypotension 54 toxicities 54 hepatic dysfunction 54 telaprevir dosing 54 caspofungin 54 Dose limiting toxicities 54 bolus dose 54 symptomatic pulmonary embolism 54 experienced hypomagnesemia 54 hematologic abnormalities 54 corticosteroid therapy 54 HIV HCV coinfected 53 Vfend 53 T2DM 53 SSRI SNRI 53 baseline HbA1c 53 VADT 53 NNT = 53 neutropaenia 53 APTIVUS 53 potassium sparing diuretics 53 anaphylactic reactions 53 DOXIL 53 cardiac toxicity 53 4mg/kg 53 virologic response 53 extrapyramidal symptoms 53 lactic acidosis 53 CTEPH 53 clazosentan 53 mg dose 53 nonrandomized 53 aseptic meningitis 53 hypokalemia 53 bone marrow suppression 53 hemorrhagic strokes 53 BENCHMRK 53 thromboembolism 53 torsades de pointes 53 nasopharyngitis 53 acute phosphate nephropathy 53 pruritis 53 risperidone Risperdal 53 SREs 53 headache abdominal pain 53 VP# [004] 53 CAMMS# 53 TMC# r 53 evaluable patients 53 HMG CoA reductase inhibitors 53 endometrial hyperplasia 53 Elitek 53 pathologic fractures 53 comparator arm 53 quinolone antibiotics 53 abatacept 53 patients receiving ERBITUX 53 CCyR 53 HF hospitalization 53 PDE4 inhibitors 53 intraocular inflammation 53 adrenal insufficiency 53 ziconotide 53 REMICADE ® 53 treatment naive genotype 53 null responders 53 cerivastatin 53 bacteraemia 53 nonfatal cardiovascular 53 Angioedema 53 placebo controlled trials 53 elevated liver enzymes 53 headache nasopharyngitis 53 highly emetogenic 53 advanced adenoma 53 cytopenias 53 lipid lowering agents 53 poor metabolizers 53 cIAI 53 mITT 53 anakinra 53 ocular toxicity 53 symptomatic VTE 53 concomitant AEDs 53 octreotide LAR 53 postoperative infections 53 gastrointestinal perforation 53 relapsed MM 53 adverse reactions incidence 53 CIMZIA TM 53 BENICAR HCT 53 aldosterone antagonist 53 TMP SMX 53 sirolimus stent 53 VaD 53 neutropenia febrile neutropenia 53 invasive candidiasis 53 MGUS 53 gastrointestinal adverse reactions 53 IgA deficiency 53 microscopic hematuria 53 Discontinuations 53 underwent CABG 53 mITT population 53 antiarrhythmic drug 53 decitabine 53 oral olanzapine 53 URTI 53 BPS IC 53 hyperkalemia 53 Multiple Ascending Dose 53 mg q#h 53 cerebral vasospasm 53 telithromycin 53 colorectal adenoma 53 fosamprenavir 53 diarrhea nausea vomiting 53 Virologic failure 53 atherothrombotic 53 subanalysis 53 lipid parameters 53 Polyp Prevention Trial 53 hematological toxicity 53 efalizumab 53 nondiabetic patients 53 GnRH agonists 53 clinico pathological 53 hematologic toxicities 53 polyarticular 53 limiting toxicity 53 non hematological toxicities 53 REMINYL ® 53 ROTATEQ 53 Exclusion criteria 53 SIMPADICO 53 postintervention 53 gout flares 53 exertional heat related 52 ORENCIA ® 52 active comparator 52 HCV RESPOND 2 52 cytogenetic abnormalities 52 bovine thrombin 52 symptomatic DVT 52 osteosarcomas 52 parkinsonian symptoms 52 achieved ACR# 52 STRIDE PD 52 neutropenia thrombocytopenia 52 PASI scores 52 follicular adenoma 52 varicella infection 52 coronary stenosis 52 binary restenosis 52 lipid lowering medications 52 danazol 52 postoperative complication 52 INFERGEN 52 n = 52 seropositivity 52 NSTEMI 52 undetectable HBV DNA 52 RSV infections 52 alpha interferons 52 neurologic complications 52 cardiac valvulopathy 52 seronegative 52 vWD 52 prucalopride 52 dose cohort 52 HbA 1C 52 venous thromboembolic events 52 dose regimens 52 retrospective cohort 52 atazanavir ritonavir 52 nonresponders 52 anaphylactic reactions bronchospasm 52 leukopenia 52 chlorambucil 52 SVR# 52 KAPIDEX 52 myocardial infarction MI 52 NEUPOGEN 52 postmarketing adverse 52 elevated LDH 52 HeFH 52 DU #b 52 Serious ocular 52 PRADAXA #mg 52 NOMID 52 ibandronate 52 antiplatelet medications 52 KETEK 52 unknown etiology 52 pimecrolimus cream 52 receiving VELCADE 52 nitrofurantoin 52 REYATAZ ritonavir 52 Non inferiority 52 postoperative AF 52 paroxetine Paxil 52 PegIFN RBV 52 darunavir r 52 HBeAg seroconversion 52 LEVAQUIN 52 IIIa inhibitor 52 blinded randomized placebo controlled 52 T1DM 52 antihypertensive medications 52 aprepitant 52 ICD shocks 52 anemia leukopenia 52 darunavir ritonavir 52 hyperbilirubinemia 52 chronic urticaria 52 MRSA colonization 52 DMARD 52 Thrombocytopenia 52 serum aminotransferase levels 52 rebleeding 52 infliximab 52 neutrophil counts 52 coadministration 52 AGILECT R 52 coinfected patients 52 unstable angina pectoris 52 quetiapine 52 CYPHER Stent 52 Severe hypersensitivity reactions 52 RRMS patients 52 carotid stenosis 52 hemoptysis 52 neuropsychiatric adverse 52 enalapril 52 dose proportionality 52 infliximab Remicade 52 mcg doses 52 hypoglycaemic episodes 52 gastrointestinal toxicity 52 ACR# ACR# 52 partial remissions 52 FASLODEX 52 timepoint 52 adrenal suppression 52 tumor lysis syndrome 52 inhaled anticholinergics 52 torsade de pointes 52 Adalimumab 52 peginterferon alfa 2a 52 Mylotarg 52 ZOSTAVAX 52 symptom exacerbation 52 Tardive dyskinesia 52 PREZISTA ritonavir 52 nitrofurantoins 52 ritonavir boosted lopinavir 52 zolmitriptan 52 reflux symptoms 52 Erythropoietic therapies may 52 bicifadine 52 intraoperative complications 52 cisplatin gemcitabine 52 peginterferon 52 intravenous dosing 52 C. diff infections 52 EURIDIS 52 pyridostigmine 52 AGHD 52 arterial thrombotic 52 severe hypoglycemia 52 lacosamide 52 neutropenic fever 52 Phenoptin 52 sotalol 52 HPA axis suppression 52 carcinoids 52 unresectable HCC 52 elevated bilirubin 52 μg dose 52 asthma exacerbation 52 Cimzia TM 52 pharmacodynamic 52 mg BID 52 piperacillin tazobactam 52 LEXIVA r 52 ketoconazole 52 ischemic cardiomyopathy 52 antiretroviral naive 52 nephrotoxicity 52 Pegasys plus Copegus 52 mg BID dose 52 Meta analyzes 52 solifenacin 51 endoscopic remission 51 QD dosing 51 intermittent dosing 51 subgroup analyzes 51 SORT OUT III 51 Reversible Posterior Leukoencephalopathy Syndrome 51 heavily pretreated 51 MYCAMINE 51 seroconversion 51 efavirenz EFV 51 anticholinergics 51 nonadherence 51 subconjunctival hemorrhage 51 prednisone prednisolone 51 fenofibric acid 51 tumor regressions 51 corrected QT interval 51 CIPN 51 APTIVUS ritonavir 51 serologically active patients 51 QTc interval 51 squamous histology 51 isoproterenol 51 eplerenone 51 INTEGRILIN 51 valacyclovir 51 Hematologic 51 moderately emetogenic 51 metastatic RCC 51 mcg mL 51 NIH CPSI 51 Peg IFN 51 lymphocytosis 51 abacavir lamivudine 51 K ras mutations 51 testicular tumors 51 non selective NSAIDs 51 peripheral edema 51 mg/m2 dose 51 ß blockers 51 desvenlafaxine succinate 51 HCV genotype 1 51 HbA 1c levels 51 pharmacokinetic interactions 51 symptomatic hyponatremia 51 clinically asymptomatic 51 myocardial infarction stroke 51 remission CR 51 prior chemotherapy regimens 51 tipranavir ritonavir 51 oral Hycamtin 51 bezafibrate 51 pneumococcal serotypes 51 headache nausea diarrhea 51 paroxysmal AF 51 arthralgia 51 CDAD 51 interstitial lung disease 51 non valvular atrial 51 triamcinolone 51 QT interval prolongation 51 peginterferon alfa 2b 51 sensory neuropathy 51 beclomethasone dipropionate 51 AVELOX 51 dosing cohort 51 alicaforsen enema 51 Recurrences 51 coronary revascularization 51 vicriviroc 51 perioperative complications 51 ALLHAT 51 LOVENOX R 51 pancytopenia 51 Dermatologic toxicities 51 subtrochanteric 51 null responder HCV 51 immune thrombocytopenic purpura ITP 51 multicenter Phase III 51 cSSSIs 51 severe asthma exacerbations 51 atherothrombotic disease 51 TORISEL 51 cidofovir 51 glycated hemoglobin levels 51 O PPDS 51 follicular lymphoma FL 51 macrolide antibiotic 51 pT2 51 PEGINTRON TM 51 HCV Genotype 51 mg ustekinumab 51 adriamycin 51 DAS# remission 51 maximal doses 51 ABCB1 51 clinically meaningful improvement 51 virologically 51 nasopharyngitis headache 51 ULORIC 51 H2 receptor antagonists 51 pharmacodynamic parameters 51 ascending doses 51 arbaclofen 51 oxymorphone ER 51 budesonide pMDI 51 T2 lesions 51 atorvastatin Lipitor 51 pulmonary toxicity 51 S. aureus bacteremia 51 ACTEMRA TM 51 morphometric vertebral fractures 51 psychiatric comorbidities 51 somnolence dizziness 51 biochemical relapse 51 NLX P# 51 neurologic sequelae 51 hyperacute 51 ORENCIA 51 angiotensin converting enzyme inhibitors 51 macroalbuminuria 51 timepoints 51 nonfatal myocardial infarction 51 MIC# [001] 51 comorbid conditions 51 BANZEL 51 Discontinuation 51 acetaminophen toxicity 51 nonhematologic adverse reactions 51 GERD symptoms 51 bacteriuria 51 pharmacodynamic PD 51 PRECiSE 51 QTcF 51 confounding variables 51 interferon gamma 1b 51 myalgia 51 hyperammonemia 51 antihypertensive agents 51 plus dexamethasone 51 aminotransferases 51 irbesartan 51 ancrod 51 CA MRSA infections 51 nadolol 51 nicardipine 51 dopaminergic therapy 51 gemifloxacin 51 acute myocardial infarction MI 51 nephrotoxic 51 cSSSI 51 MMP inhibitors 51 refractory NSCLC 51 adverse cytogenetics 51 revascularization procedures 51 oral allopurinol 51 antithrombotic agents 51 sustained virological response 51 MRSA isolates 51 metastatic GIST 51 androgen deprivation 51 Dasatinib 51 salmeterol fluticasone 51 undergoing coronary angiography 51 Baseline characteristics 51 MEVACOR 51 immunocompetent 51 FLT3 mutations 51 deferiprone 51 Traficet EN 51 fluoxetine Prozac 51 CAELYX 51 CIMZIA TM certolizumab pegol 51 bosentan 51 ACTEMRA 51 anthracycline containing 51 histologic subtype 51 del 5q MDS 51 non squamous NSCLC 51 peginterferon alfa 51 HIV RNA 51 intra articular injection 51 etiologic 51 renal impairment 51 lacunar 51 corticosteroid dose 51 HbA 1c 51 linaclotide treated 51 macrovascular disease 51 aldosterone antagonists 51 cholinesterase inhibitor 51 acute gout flares 51 locoregional recurrence 50 Lucentis monotherapy 50 cholecystitis 50 angioneurotic edema 50 raltegravir 50 stage IIIB 50 LEXIVA 50 constipation nausea 50 prostate cancer CaP 50 antiandrogen 50 HSCT 50 intussusception 50 HBeAg negative 50 ipratropium bromide 50 BR.# 50 HGPIN 50 achieved statistical significance 50 mg RDEA# 50 fatal hemorrhagic 50 doxorubicin docetaxel 50 #mg/m# [001] 50 abacavir Ziagen 50 atazanavir 50 VAERS 50 mCi kg 50 superficial edema 50 underwent resection 50 sitaxsentan 50 simvastatin ezetimibe 50 recurrent ischemia 50 histologically confirmed 50 etanercept 50 â ‰ ¥ 50 oral methylnaltrexone 50 log# copies mL 50 bronchial hyperresponsiveness 50 intravitreal injections 50 dalteparin 50 severe hypoglycemic 50 myeloproliferative diseases 50 upper gastrointestinal bleeding 50 hyperprolactinemia 50 exploratory endpoints 50 mycophenolate mofetil MMF 50 XIENCE V demonstrated 50 heparin induced thrombocytopenia 50 antiarrhythmic drugs 50 JANUVIA 50 GEMZAR 50 ceftazidime 50 retrograde ejaculation 50 syncope fainting 50 HAM D# scores 50 oral prednisolone 50 CsA 50 distant metastasis 50 CIMZIA 50 Subgroup analyzes 50 Folfox 50 Telintra 50 goserelin 50 ocrelizumab 50 clinically meaningful improvements 50 doxorubicin cyclophosphamide 50 GH deficiency 50 ≥ 50 receiving VICTRELIS 50 paresthesias 50 SPIRIVA HandiHaler 50 Secondary endpoints 50 administered subcutaneously 50 BEXXAR Therapeutic Regimen 50 prescribed opioids 50 prespecified secondary 50 malignant polyps 50 NOXAFIL 50 receiving ISENTRESS 50 serum IGF 50 thiopurine 50 urate lowering 50 CLL SLL 50 MADRS score 50 receiving XGEVA 50 INVEGA ® 50 DAS# scores 50 pH#N# 50 haloperidol Haldol 50 Noxafil 50 amiodarone 50 aripiprazole Abilify 50 #mg BID [003] 50 serum phosphorous 50 NRTI 50 pCR 50 PML progressive multifocal 50 amoxicillin clavulanate 50 SGAs 50 LAMICTAL 50 lispro 50 thrombotic thrombocytopenic purpura TTP 50 clinically meaningful reductions 50 serum phosphorus 50 microgram kg 50 nevirapine Viramune 50 ribavirin RBV 50 hyperoxaluria 50 androgen suppression 50 8mg/kg 50 zonisamide SR 50 congenital anomalies 50 statistically significant p = 50 ritonavir boosted 50 LVEF 50 stomatitis 50 pharmacokinetics PK 50 saline placebo 50 levetiracetam 50 ritonavir boosted protease inhibitor 50 LTBI 50 fosbretabulin 50 liver toxicity 50 Secondary efficacy endpoints 50 gemfibrozil 50 mg QD 50 papillary renal cell carcinoma 50 resuscitated cardiac arrest 50 gastric ulcers 50 MAS XR 50 COPERNICUS 50 L lysine 50 MULTAQ 50 antiemetics 50 seroconverted 50 fluoxetine paroxetine 50 serum BDNF 50 null responder 50 Asymptomatic 50 WARNINGS Myopathy Rhabdomyolysis 50 motorcoach crashes 50 prospectively enrolled 50 fatigue asthenia 50 Psoriasis Area 50 coinfected 50 vertebral fracture 50 Zevalin consolidation 50 syndromic 50 umol L 50 symptomatic BPH 50 Kaplan Meier estimates 50 insulin detemir 50 AML MDS 50 amphotericin B 50 neuroleptic malignant syndrome 50 NAbs 50 RISPERDAL ® 50 Crohn Disease Activity 50 ceftriaxone 50 Alequel 50 mCi 50 serum leptin 50 INTELENCE 50 leukotriene receptor antagonists 50 delayed CINV 50 renal insufficiency 50 Kepivance 50 SJIA 50 Postmarketing 50 FOLFOX4 50 clinically relevant 50 Cardiotoxicity 50 logistic regression models 50 glomerular filtration 50 epoetin alpha 50 visilizumab 50 penicillin allergy 50 KRAS status 50 virological response 50 benazepril 50 IRLS score 50 pulmonary exacerbations 50 oral antidiabetes drugs 50 Lamictal XR 50 HCV genotype 50 mucositis 50 mg kg Hematide 50 thrombocytopenia neutropenia 50 ONGLYZA saxagliptin 50 post herpetic neuralgia PHN 50 observational cohort 50 divalproex sodium 50 noninferiority 50 Lactic acidosis 50 liver transplant recipients 50 lymphopenia 50 preintervention 50 risperidone olanzapine 50 QTc intervals 50 nonmetastatic prostate cancer 50 MIRAPEX 50 receiving Vectibix monotherapy 50 mg TID 50 Eltrombopag 50 serotype #A 50 systemic corticosteroid 50 Adentri 50 recurrent glioblastoma multiforme 50 ARCALYST 50 CVD mortality 50 Hb levels 50 fatal myocardial infarction 50 fondaparinux 49 antithrombotic therapy 49 PROMACTA 49 events MACE 49 dapsone 49 certolizumab pegol 49 Efficacy endpoints 49 L thyroxine 49 ENGAGE AF TIMI 49 TELINTRA 49 recurrent ischemic 49 statistically significant p 49 sulfonamides 49 RESIST studies 49 HCV infected 49 angiographically 49 undergone splenectomy 49 alanine aminotransferase 49 Novantrone 49 SUSTIVA 49 adefovir treated 49 ACTOplus met XR 49 #mg dose [001] 49 conjunctival hyperemia 49 cardiac repolarization 49 postexposure prophylaxis 49 LPV r 49 dapagliflozin plus 49 visceral metastases 49 venous blood clots 49 serotonin syndrome 49 serum calcium 49 mcg linaclotide 49 hepatic toxicity 49 mg Proellex 49 acneform rash 49 meta regression 49 postvaccination 49 paroxetine sertraline